INTRODUCTION
After several years of managing cholangitis in biliary atresia (BA), we recognized that a small group of patients required prolonged intravenous (IV) antibiotic treatment to prevent recurrent cholangitis. In this group, oral antibiotic treatment was not effective enough to prevent cholangitis, and the discontinuation of IV antibiotic treatment led to recurrent cholangitis attacks. Thus, these patients had intractable cholangitis (IC) that could not be controlled by routine conservative treatment. In addition, the IC was usually associated with intrahepatic biliary cysts (IHBCs) and required hospitalization for several months or several years. The long period of hospitalization occasionally resulted in the breakup of the patient's family, which would be "the worst disaster for the patients." For thesurgery.or.kr the management of IC, we developed a home intravenous antibiotic treatment (HIVA) based on the idea of home total parenteral nutrition (TPN) for short bowel syndrome.
To evaluate the role of HIVA in patients with IC following Kasai portoenterostomies, we reviewed records of 10 patients who had been treated at our institution.
METHODS
We retrospectively reviewed medical records of patients who had been treated with HIVA for IC after successful Kasai portoenterostomies performed for BA be- When fever subsided and cholangitis was controlled with optimal intravenous antibiotics treatment during hospitalization, a Broviac catheter (Bard Access Systems Inc., Salt Lake City, UT, USA) was placed in the central vein of the patients before they were discharged from the hospital. The catheter was inserted under general anesthesia, and remained for the full course of HIVA. After discharge, home care nurse or the patients' parent(s) or guardians administered intravenous antibiotic treatment via the catheter in the same way it was done during hospitalization. To prevent re-hospitalization due to the recurrent cholangitis a few days later after discharge, they were managed with HIVA after discharge. They were checked up every month at out-patient clinic.
During monthly follow-up at out-patient clinic, the completion time for HIVA was determined. Kasai portoenterostomies were unsuccessful in nine patients. The levels of serum bilirubin never dropped to less than 2 mg/dL after these nine Kasai procedures. Three patients among these nine patients presented with IC.
Eighty-one patients were followed-up after successful Kasai procedures. Another patient was referred to our in- Time from the diagnosis of IC to the start of HIVA; c)
Case underwent Kasai procedure at another hospital. 2) . In spite of those many attempts, cholangitis attacked recurrently in those two patients. A few days after they were discharged from long hospitalization, they suffered from recurrent cholangitis and were re-admitted. Before Case of liver transplantation due to esophageal variceal bleeding at 31 months after HIVA. Cholangitis recurred a few times after completion of HIVA in patients 1, 2, and 5 ( Fig. 2) . However, it was easily controlled with routine conservative management in hospitalization. All patients, except one (patient 3) who underwent liver transplantation due to variceal bleeding, are free of IC with native liver on last follow-up (median duration of follow-up: 58 months after HIVA) as shown in Table 2 . All patients with native liver showed acceptable hepatic function and were jaundice-free. Their serum levels of total bilirubin on last follow-up are listed in Table 2 .
IHBCs disappeared on the follow-up abdominal ultrasonography within 2 years after the completion of HIVA in all patients who were followed up. Recurrent IHBCs associated with cholangitis were detected on long-term (more than 2 years) follow-up in only the first two patients for whom application of HIVA was delayed (Table 2) The median hospital stay with conventional treatment before HIVA was 5.7 days per month and, after HIVA, 1.5 days per month for eight patients for whom this data was recorded. This decrease in the admission rate after the completion of HIVA was significant (P = 0.012) ( Table 3 ).
The median amount of medical expenses for IC was about 
DISCUSSION
Cholangitis is a common complication that develops after Kasai procedures for BA [1] . The reported incidence of postoperative cholangitis in BA ranges from 40 to 93% [2] .
IC that cannot be controlled by routine conservative treatment may lead to biliary cirrhosis and hepatic failure with portal hypertension. IC is considered as one of the most important and difficult complications to manage after thesurgery.or.kr Kasai portoenterostomy because of the poor prognosis and the occasional requirement of liver transplantation.
Recurrent cholangitis is one of the most important determinants of prognosis after a successful Kasai procedure.
The number of cholangitis episodes negatively affects long-term postoperative survival. IHBCs favor bacterial persistence and cause recurrent cholangitis [3] . The reported incidence of IHBCs after hepatic portoenterostomy in biliary atresia ranges from 6.4 to 25.3% [4] [5] [6] [7] . Major complications that induce mortality from recurrent cholangitis include massive variceal bleeding and hepatic failure [8] . Many surgical and medical treatments have been suggested for cholangitis and IHBCs, including systemic antibiotic therapy [4, 7] , percutaneous transhepatic cholangiodrainage (PTCD) [4, 5, 7, 9] , alcohol injections [4] , revision of portoenterostomy [4, 10] , laparotomy with internal intestinal drainage of an IHBC [5] , Roux-en-Y reconstruction by limb lengthening and antireflux valve creation for mechanical problems related to bile drainage in Roux-en-Y limb [11] , and liver resection for the localized IHBC [12] .
These treatment modalities are limited in their ability to manage refractory cholangitis or IHBCs. PTCD is not effective in cases of noncommunicating cysts, and is difficult if the cysts are located in the porta hepatis because of the risk of jejunal or portal injury [4] . Bu et al. [7] reported that IHBCs disappeared with PTCD in only one of 39 patients with multiple IHBCs. Surgical intervention is also difficult to perform if cysts are located in the deep portion of the liver [4] . In the first two patients (patients 1 and 2) of 10 patients who received HIVA, huge IHBC was drained by PTCD to resolve the IC because the IHBCs detected on imaging study were considered to be the infectious source of IC (Fig. 3A) . However, cholangitis was not controlled by PTCD. We struggled to control IC with other interventions. To control IC in these initial two patients, we performed alcohol injections via the PTCD catheter, hepatic cystojejunostomy, internal metal stent insertion, or revision of portoenterostomy, but cholangitis still did not resolve (Fig. 2, 3B) Three patients who suffered from IC after successful Kasai portoenterostomies did not respond to continuous IV antibiotics treatment while being hospitalized. In these patients, HIVA could not be applied (Fig. 1) . One of them 
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